The use of live attenuated intravesicular Bacillus Calmette-Guerin (BCG) therapy is a generally accepted safe and effective method for the treatment of superficial transitional cell carcinoma (TCC) of the bladder. Although rare, < 5% of patient's treated with intravesicular BCG therapy may develop potentially serious complications, including localized infections to the genitourinary tract, mycotic aneurysms and osteomyelitis. We present here a case of a 63-year-old male who developed left coronary and multiple peripheral M. Bovis mycotic aneurysms as a late complication of intravesicular BCG therapy for superficial bladder cancer. The patient initially presented with acute onset pain and swelling in the left knee > 2 years following initial therapy, and initial workup revealed a ruptured saccular aneurysm of the left popliteal artery as well as incidental bilateral common femoral artery aneurysms. Following endovascular treatment and additional workup, the patient was discovered to have additional aneurysms in the right popliteal artery and left anterior descending artery (LAD). Surgical pathology and bacterial cultures obtained from the excised femoral aneurysms and surgical groin wounds were positive for Mycobacterium Bovis, and the patient was initiated on a nine-month antimycobacterial course of isoniazid, rifampin and ethambutol. Including the present case, there has been a total of 32 reported cases of mycotic aneurysms as a complication from intravesicular BCG therapy, which we will review here. The majority of reported cases involve the abdominal aorta; however, this represents the first known reported case of a coronary aneurysm.
In March of 2015, the patient presented to the Emergency Department (ED) after the acute onset of left knee pain and swelling. A venous Doppler ultrasound (US) was performed in the ED, demonstrating a complex vascular mass arising from the popliteal artery consistent with a partially thrombosed popliteal aneurysm [Figure 1a, b] . In addition, a partially thrombosed left common femoral aneurysm was identified [Figure 1 c, d] . He received a CTA immediately afterwards, which demonstrated a 5.5 x 6.5 cm ruptured left popliteal aneurysm [ Figure 2a ] and incidental bilateral common femoral artery (CFA) aneurysms [Figure 2b, c] . Mild scattered calcified atherosclerotic plaque was noted in the inflow vessels, without significant stenosis.
The patient was stabilized and subsequently underwent left popliteal artery covered stent placement by vascular surgery and interventional radiology the following day. He had an uneventful post-operative course and was discharged shortly afterwards with future plans for elective repair of the bilateral CFA aneurysms.
In May of 2015, the patient returned to the ED with acute onset pain and swelling behind the right knee. Doppler US demonstrated a ruptured right popliteal aneurysm in addition to enlarging bilateral CFA aneurysms [ Figure 3 ]. He received endovascular repair of the ruptured popliteal aneurysm with a covered stent the following day, followed by open surgical repair of the CFA aneurysms with bilateral interposition grafts the following week [Figure 4, 5] . Pathology results from the excised femoral aneurysms demonstrated the presence of acid bacilli on AFB stains, consistent with mycobacterial infection. The post-operative course was prolonged and complicated by non-healing bilateral surgical groin wounds and progressive weight loss. On post-op day 12, the patient also developed fevers and chills. These developments led to an extensive but unremarkable workup for potential sources of infection and occult malignancy, including a negative CT of the chest, abdomen and pelvis and multiple negative blood cultures. One month post-op, the patient underwent bilateral groin wound washout with wound VAC placement. Wound cultures obtained at the time of surgery, were positive for Mycobacterium Bovis, consistent with the previous pathology findings. Given the diagnosis of M. Bovis induced mycotic aneurysms, the patient underwent CTA of the head, neck, chest, abdomen and pelvis to screen for additional aneurysms, which were reported as negative for additional aneurysms. Infectious Disease was consulted, who initiated a 9-month course of anti-mycobacterial treatment with Isoniazid, Rifampin and Ethambutol.
Two months following the initial diagnosis, the patient underwent surveillance CTA of the lower extremities to evaluate patency of the surgical interposition grafts. The results demonstrated patent surgical grafts; however, enlarging mycotic aneurysms were discovered in the proximal right common iliac artery and at the distal attachment site of the right surgical interposition graft [ Figure 6 ]. The following week, the patient underwent endovascular repair with a bifurcated distal aortic stent graft and coil embolization of the right common iliac aneurysm [ Figure 7 ]. There was no evidence of new or enlarging aneurysms on 2-month follow-up CTA [ Figure 8 ].
Over the next month, the patient had complaints of increased pain and swelling behind the right knee. CTA of the lower extremities was performed which showed an enlarging hematoma in the right popliteal fossa [ Figure 9a , b]. In addition, there appeared to be an enlarging partially thrombosed aneurysm arising from the mid LAD, which, in retrospect, was present on screening CTA performed two months earlier [Figure 9 c, d] . The patient subsequently received a dedicated coronary CTA to further evaluate this new finding. Results demonstrated a large saccular aneurysm with sluggish internal flow arising from the mid LAD with resultant mass effect on the left ventricular outflow tract [ Figure 10 ]. In lieu of the newly discovered LAD aneurysm, cardiothoracic surgery was consulted who deemed that no surgical intervention was warranted at that time due to the poor functional and nutritional status of the patient. Alternatively, a coronary catheter angiogram was performed by interventional cardiology to evaluate the possibility of stent placement; however, stent placement was precluded by occlusion of the mid LAD at the aneurysm site [ Figure 11 ].
Given the rapid interval growth of the LAD mycotic aneurysm and the patient's poor functional status, his longterm prognosis was deemed poor. As such, the patient was placed on the palliative care service and converted to a DNR status. He continues to receive antiomycobacterial therapy in attempt to prevent interval mycotic aneurysm growth and formation. Currently the patient is undergoing subacute rehabilitation with the aims of improving his functional and nutritional status for the future possibility of potential surgical repair.
Etiology & Demographics:
Bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis that was initially developed as a vaccination against Mycobacterium tuberculosis infection. In 1976, BCG was introduced as a primary treatment for superficial transitional cell carcinoma (TCC) of the urinary bladder with a reported cure rate of 70% [1] . Intravesicular BCG therapy is generally considered safe with the most common reported side effects of low-grade fever, dysuria, urinary frequency and malaise with a typical onset within 2-4 hours following therapy and resolving within 48 hours [2, 3, 24, 29] .
In < 5% of cases, more serious localized or disseminated infections due to BCG may occur. The largest reported series followed 2,602 patients who received BCG therapy. In this group, granulomatous prostatitis occurred in 0.9% of patients, hepatitis occurred in 0.7% of patients and pneumonitis in 0.7% of patients [3] . The onset of symptoms following initial treatment is variable and some authors have divided complications into early (< 6 months) and late complications (> 6 months) [4, 5] . A retrospective review of 41 patients who developed treatment complications DISCUSSION demonstrated that slightly more than half (25/41) of patients were considered early-onset and tended to manifest with nonspecific systemic symptoms (fever, chills, malaise and weight loss) due to an inflammatory response. On the contrary, the remaining 16/42 patients who developed late-onset disease tended to develop more localized infections due to BCG reactivation, with the most common site involving the genitourinary tract followed by the vascular system, skeleton and retroperitoneal soft tissues [4, 24] .
The incidence of BCG-induced mycotic aneurysms following intravesicular infusion is exceedingly rare. Including the current case, there have only been 32 reported cases, with all but one occurring in middle-aged or elderly men [ Table 3 ]. The majority of reported cases (26/32) involve the thoracic or abdominal aorta [6-33, Table 1 ]. Approximately one-fourth of reported cases involve the peripheral vascular system of the lower extremities (9/32) and there have been three reported cases involving the carotid arteries [ Table 1 ]. To our knowledge, the current patient marks the first reported case of a Mycobacterium bovis mycotic aneurysm of a coronary artery following intravesicular BCG therapy for bladder cancer.
The exact mechanism for mycotic aneurysm formation is unknown. Potential proposed mechanisms for BCG infection include direct intimal colonization from hematogenous spread, metastatic implantation through the vasa-vasorum or local vascular extension from an adjacent infectious site [5, 22] . Accordingly, the most important known risk factor for BCG infection is disruption of the urogenital mucosa at the time of bladder instillation, including traumatic indwelling catheter insertion, recent biopsy, surgery or active cystitis [2, 22] . Some authors have proposed the use of prophylactic isoniazid at the time of BCG instillation, however this has not been shown to be effective [34] . Most authors now advise delaying BCG therapy for several weeks following cystitis, bladder resection, biopsy or difficult catheterizations [22] .
Clinical & Imaging Findings:
The diagnosis of M. bovis mycotic aneurysms is difficult and remains elusive owing to the nonspecific clinical findings and relatively low incidence of occurrence. Diagnosis is often delayed, with the mean time of diagnosis occurring 23 months (range 4-69 months) following BCG therapy [5] . Patients usually present with fever of unknown origin, weight loss, a palpable abdominal mass and rarely signs/symptoms of aneurysm rupture. The gold standard for definitive diagnosis is bacterial cultures; however, this requires a minimum incubation period of 6-8 weeks and acid-fast stains require a minimum of 10,000 organisms per gram of tissue to yield positivity [5, 26] .
The imaging findings are relatively straightforward but also nonspecific, demonstrating typical findings for mycotic or inflammatory aneurysms such as saccular aneurysms of medium or large-caliber arteries and associated perivascular inflammation [ Tables 1, 2 ]. Catheter angiography remains the gold standard for imaging diagnosis of mycotic aneurysms, but its use is variable based on local expertise and limited by invasiveness. Multidetector CT angiography is the current imaging modality of choice for the evaluation of suspected mycotic aneurysms, with the advantages of rapid image acquisition, high sensitivity, widespread availability, high spatial resolution and multi-planar capabilities [35] . Mycotic aneurysms commonly appear as saccular dilatations of arteries not commonly involved by atherosclerosis (i.e. peripheral arteries), although the infrarenal abdominal aorta is still the most common reported site of mycotic aneurysms. Associated findings of perivascular inflammatory change and relative lack of atheromatous wall calcifications increases the specificity for mycotic aneurysm [ Table 2 ]. MR angiography demonstrates similar findings as CTA but is limited by long acquisition times, availability, motion susceptibility and relatively lower spatial resolution [35] . As in our patient, ultrasound is mainly limited to mycotic aneurysms of the peripheral arteries and is as not reliable at diagnosing visceral or abdominal aortic aneurysms
Treatment & Prognosis:
The treatment of severe systemic BCG reactions includes a combination of medical and surgical/interventional therapy. The International Bladder Cancer Group recommends discontinuation of BCG therapy, initiation of high-dose fluoroquinolones, corticosteroids and daily antimycobacterial therapy with isoniazid, rifampin and ethambutol for six months duration [24] . It is well established that this particular strain of Mycobacterium is resistant to pyrazinamide [36] . In regards to treatment of the aneurysm itself, the mainstay of therapy in the reported literature has been surgical stent-grafting, or less commonly surgical bypass procedures. Of the 32 reported cases 68% (22/32) underwent a surgical graft procedure [ Table  1 ].
As endovascular aneurysm repairs are becoming increasingly more popular for the treatment of non-mycotic aneurysms due to decreased peri-operative morbidity and mortality, some have suggested that endovascular repair should be the exclusive means for treating mycotic aneurysms [37] . The data on endovascular repair of mycotic M. bovis aneurysms, however, is scarce. To our knowledge, there have only been two reported cases of primary repair by endovascular stent-graft placement [12, 33] . One patient was treated with EVAR for a mycotic AAA and died due to a MI as a perioperative complication [12] . The other patient was also treated with an EVAR but lost to follow-up (left the hospital against medical advice, 33]. With regards to treatment of peripheral M. bovis mycotic aneurysms, all of the previous reported cases have undergone surgical treatment as the primary means of repair with generally good results [7, 8, 15, 16, 17, 19, 20, 23, 30] . To our knowledge, the current patient marks the first reported case of primary endovascular repair with covered stents for peripheral BCG aneurysms. Furthermore, this also marks the first known reported case of a BCG-induced coronary aneurysm. As such, no established guidelines for treatment exist and the prognosis remains unknown.
Differential Diagnosis:
The main differential diagnosis for mycotic aneurysms on imaging is relatively limited and includes atherosclerotic aneurysms, inflammatory aneurysms, contained aneurysm rupture and aortoenteric fistulas [ Table 2 ]. Once mycotic aneurysms are suspected, it is very important to correlate findings with a detailed history and physical. Although rare, any patient with a recent or prior history of BCG therapy for bladder cancer should yield a lower threshold for the consideration M. bovis mycotic aneurysm in these patients.
Atherosclerotic aneurysm: This is the most common etiology for aneurysm and typically occurs in males older than 50 years of age with atherosclerotic risk factors (i.e. hypertension, smoking, diabetes). The most common location is the infrarenal aorta and manifests on imaging as fusiform dilatation with calcified and fibrofatty wall plaque. Furthermore, if an aneurysm is encountered within a coronary artery, it is most likely to be atherosclerotic in etiology.
Inflammatory aneurysm:
Inflammatory aneurysms typically occur in patients with similar risk factors to atherosclerotic aneurysms, but are generally found about a decade earlier and present with systemic inflammatory symptoms (i.e. fever, weight loss, elevated ESR). Similar to atherosclerotic aneurysms, inflammatory aneurysms present with fusiform dilatation of the infrarenal aorta; however, imaging will also demonstrate signs of inflammation (i.e. thickening aortic wall, peri-vascular stranding and/or fluid).
Contained aneurysm rupture: Patients with aneurysms of any etiology may occasionally present with a contained rupture. Clinically, patients will often present with acute onset abdominal or back pain with or without hemodynamic instability. The most reliable sign on imaging is the presence of focal wall discontinuity within a calcified aneurysm wall with associated peri-aneurysmal fluid. Conventional catheter angiography might demonstrate active arterial extravasation if the rupture is ongoing.
Aortoenteric fistula: Defined as an abnormal fistulous connection between small bowel and the aorta, this typically occurs in the setting of prior retroperitoneal surgery, most commonly surgical AAA repair. Patients may present acutely with a brisk lower gastrointestinal bleed. Imaging will demonstrate loss of the normal fat plane between small bowel and abdominal aorta, and if present, gas within the aorta is highly suggestive of aortoenteric fistula.
Bacillus Calmette-Guerin (BCG) is a generally safe and accepted method for the treatment of superficial transitional cell carcinoma (TCC) of the bladder. In rare instances, BCGactivation may result in the serious complication of mycotic aneurysm formation, which typically manifests months-toyears following therapy as mycotic AAA, or less commonly mycotic peripheral aneurysms. Therapy consists of cessation of ongoing BCG therapy, antimycobacterial therapy and surgical/endovascular aneurysm repair. .7 x 4.1 cm thrombosed aneurysm (cyan arrow) which appears to arise from the LAD (yellow arrow). In retrospect, this aneurysm was present on screening CTA of the chest performed 49 days earlier and measured 1.6 x 1.6 cm at that time (white arrow). Technique: GE Lightspeed, 16 channel, mAs 10,400, kVP 120, slice thickness 2.5 mm; Contrast material: 125 mL Omnipaque 350 mg/ml injected at a rate of 5 ml/s. Findings: (a-d) -Dynamic images obtained during injection of the left main coronary artery (white arrow) demonstrates a focal caliber change in the mid LAD (blue arrow). An amorphous collection of contrast is noted adjacent to the mid LAD, which progressively fills a large saccular aneurysm sac arising from the mid LAD (curved red arrow). There is no opacification of the LAD distal to the aneurysm site, indicating occlusion of the distal LAD. The left circumflex artery appears normal (curved yellow arrow). Technique: Fluoroscopy time 6.2 minutes; DAP 49 mGy-m2; Contrast material: 70 mL Omnipaque 350 mg/ml.
